JNJ Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
25.4B
+0.4%
25.3B
+5.2%
24.1B
-2.0%
24.6B
+2.4%
24.0B
Cost of Revenue
8.1B
+0.6%
8.1B
-0.7%
8.1B
+1.7%
8.0B
+9.1%
7.3B
Gross Profit
17.3B
+0.2%
17.3B
+8.2%
16.0B
-3.9%
16.6B
-0.6%
16.7B
Operating Expenses
11.5B
+13.2%
10.1B
+5.1%
9.6B
-13.8%
11.2B
+15.7%
9.7B
R&D
5.0B
+36.6%
3.7B
+2.5%
3.6B
-17.8%
4.3B
+18.0%
3.7B
SG&A
6.3B
-2.3%
6.4B
+6.6%
6.0B
-10.6%
6.8B
+14.0%
5.9B
Operating Income
5.8B
-18.1%
7.1B
+12.8%
6.3B
+16.6%
5.4B
-22.8%
7.0B
EBITDA
8.1B
-10.8%
9.1B
+9.2%
8.4B
+11.2%
7.5B
-15.2%
8.9B
Net Income
210.0M
-96.2%
5.5B
+5.7%
5.2B
+2.3%
5.1B
-0.7%
5.2B
EPS (Basic)
$0.09
-96.1%
$2.30
+6.0%
$2.17
+2.4%
$2.12
-0.9%
$2.14
EPS (Diluted)
$0.09
-96.0%
$2.27
+6.1%
$2.14
+2.4%
$2.09
-1.4%
$2.12
Shares (Diluted)
2.4B
+0.3%
2.4B
-0.2%
2.4B
-0.0%
2.4B
+0.7%
2.4B
Johnson & Johnson (JNJ) โ€” Financials